SCHEMBL1123696

SCHEMBL1123696

COC(=O)c1nnc2ccccc2c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
STAT3 P40763 1/20 0.47
HIF1A Q16665 1/20 0.47
LCK P06239 1/20 0.46
MAP2K3 P46734 1/20 0.46
MAP2K6 P52564 1/20 0.46
BTK Q06187 1/20 0.46
MAP3K19 Q56UN5 1/20 0.46
NEK10 Q6ZWH5 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PADI4 Q9UM07 1/20 0.43
F2 P00734 1/20 0.42
PLAU P00749 1/20 0.42
ELANE P08246 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10861354 0.83 KDM4E (0.51) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL1123455 0.82 KDM4E (0.50) KDM4ESTAT3HIF1ALCKMAP2K3
SCHEMBL2294851 0.81 MEN1 (0.49) KDM4ESTAT3HIF1ALCKMAP2K3
SCHEMBL9338870 0.80 SMN1; SMN2 (0.59) KDM4ESTAT3HIF1ALCKMAP2K3
SCHEMBL7706331 0.79 LCK (0.51) KDM4ELCKMAP2K3MAP2K6BTK
SCHEMBL31371878 0.79 LCK (0.51) KDM4ELCKMAP2K3MAP2K6BTK
SCHEMBL15757451 0.78 KDM4E (0.49) KDM4ESTAT3HIF1AMEN1KMT2A
SCHEMBL9524647 0.78 ALDH1A1 (0.46) KDM4ELCKMAP2K3MAP2K6BTK
SCHEMBL8569494 0.78 MEN1 (0.56) KDM4ESTAT3HIF1AMEN1KMT2A
SCHEMBL9525498 0.77 LCK (0.50) KDM4ELCKMAP2K3MAP2K6BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309552-B2 Immunomodulating heterocyclic compounds MEDIGENE AG (DE) 2012-11-13 US disclosed
US-8309552-B2 Immunomodulating heterocyclic compounds MEDIGENE AG (DE) 2012-11-13 US disclosed
US-8309552-B2 Immunomodulating heterocyclic compounds MEDIGENE AG (DE) 2012-11-13 US disclosed
EP-2284172-A1 Immunomodulating heterocyclic compounds MediGene Ltd. (GB) 2011-02-16 EP disclosed
EP-1603917-B1 IMMUNOMODULATING HETEROCYCLIC COMPOUNDS MEDIGENE LTD (GB) 2010-11-24 EP disclosed
EP-1603917-B1 IMMUNOMODULATING HETEROCYCLIC COMPOUNDS MEDIGENE LTD (GB) 2010-11-24 EP disclosed
US-20090312334-A1 Immunomodulating Heterocyclic Compounds MEDIGENE LIMITED (GB) 2009-12-17 US disclosed
US-20090312334-A1 Immunomodulating Heterocyclic Compounds MEDIGENE LIMITED (GB) 2009-12-17 US disclosed
US-20090312334-A1 Immunomodulating Heterocyclic Compounds MEDIGENE LIMITED (GB) 2009-12-17 US disclosed
US-7598247-B2 Immunomodulating heterocyclic compounds MEDIGENE LIMITED (GB) 2009-10-06 US disclosed
CN-100363365-C Immunomodulating heterocyclic compounds AVIDEX LTD (GB) 2008-01-23 CN disclosed
US-7276505-B2 Immunomodulating heterocyclic compounds MEDIGENE LIMITED (GB) 2007-10-02 US disclosed
US-7276505-B2 Immunomodulating heterocyclic compounds MEDIGENE LIMITED (GB) 2007-10-02 US disclosed
US-7276505-B2 Immunomodulating heterocyclic compounds MEDIGENE LIMITED (GB) 2007-10-02 US disclosed
US-20070021428-A1 Immunomodulating heterocyclic compounds AVIDEX LIMITED (GB) 2007-01-25 US disclosed
US-20070021428-A1 Immunomodulating heterocyclic compounds AVIDEX LIMITED (GB) 2007-01-25 US disclosed
US-20070021428-A1 Immunomodulating heterocyclic compounds AVIDEX LIMITED (GB) 2007-01-25 US disclosed
CN-1761664-A Immunomodulating heterocyclic compounds AVIDEX LTD (GB) 2006-04-19 CN disclosed
EP-1603917-A1 IMMUNOMODULATING HETEROCYCLIC COMPOUNDS Avidex Limited (GB) 2005-12-14 EP disclosed
WO-2004081011-A1 IMMUNOMODULATING HETEROCYCLIC COMPOUNDS AVIDEX LIMITED (GB) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312334-A1 Immunomodulating Heterocyclic Compounds CD40, CD40LG, NGFR KDM4E 1911/4885STAT3 793/4885HIF1A 2184/4885
US-20070021428-A1 Immunomodulating heterocyclic compounds CD40, CD40LG, NGFR KDM4E 2050/4885STAT3 778/4885HIF1A 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.